MedTrace Logo

A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities

NCT05051579 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 272

Last updated 2023-09-13

Study results available
· View outcomes & findings →

Summary

The main purpose of the study was to assess the effect of LY3502970 in participants who have obesity or are overweight.

Conditions

Interventions

DRUG

LY3502970

Administered orally

DRUG

Placebo

Administered orally

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-5615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-29
Primary Completion
2022-08-25
Completion
2022-11-22
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Hungary
  • Puerto Rico

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05051579 on ClinicalTrials.gov